Previously identified bladder cancer markers have been of limited utility in clinical applications owing to the variable (HRAS; Fitzgerald et al, 1995) or low (<20%; CCND1; Hovey et al (1998); and ERBB2; Bringuier et al (1996) frequency of altered expression or activity in tumours. Here, ERBB2 is linked to neoplasm.